Altimmune, Inc. (ALT) Stock: A Biotech Stock That’s Headed Up


Altimmune, Inc. (ALT) is making a move up in the market today. The company, one that is focused on the biotechnology space, is presently priced at $2.88 after a move up of 6.80% so far today. When it comes to biotechnology stocks, there are quite a few factors that have the ability to lead to gains in the market. News is one of the most common reasons for movement. Here are the most recent trending headlines associated with ALT:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-14-19 09:00AM Altimmune to Participate at 31st Annual ROTH Conference
Mar-12-19 01:34PM Altimmune Announces Closing of $14 Million Registered Direct Offering
Mar-08-19 09:29AM Altimmune Announces $14 million Registered Direct Offering
Jan-29-19 08:00AM Altimmune Announces Presentation of HepTcell Phase 1 Results at The International Liver Congress in Vienna, Austria
Dec-14-18 07:00AM Today’s Research Reports on Trending Tickers: Sage Therapeutics and Altimmune

However, when making a decision to invest, investors should look into far more than just news, especially in the highly speculative biotechnology sector. Here’s what’s happening with Altimmune, Inc..

Recent Movement Out of ALT

While a move toward the top in a single session, like the gain that we’re seeing from Altimmune, Inc. might lead to excitement in some investors, a single session move alone should not be the basis of a decision to, or not to, invest in a stock. It is generally a good idea to dig into trends further out than a single trading session. When it comes to ALT, below are the movements that we’ve seen:

  • Weekly – Over the last seven days, ALT has produced a price change amounting to -6.25%.
  • Monthly – The monthly ROI from Altimmune, Inc. works out to -11.48%.
  • Past Three Months – Over the last 3 months, the stock has generated a ROI of -11.48%
  • Past Six Months – In the past six months, we’ve seen a change that amounts to -68.76% from the stock.
  • This Year So Far – Since the close of last year ALT has produced a ROI of 31.07%.
  • Annually – Lastly, over the past year, we have seen movement of -94.77% out of ALT. Throughout this period of time, the stock has traded at a high price of -94.38% and a low price of 69.62%.

Ratios To Pay Attention To

Looking at various key ratios having to do with a company can provide investors a view of how dangerous and/or potentially profitable a pick may be. Here are a few of the important ratios to look at when looking at ALT.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors are expecting that the price of the stock is going to fall. In general, biotech stocks can have a higher short ratio. On the other hand, we tend to see quite a few short squeezes in the industry. Nonetheless, with regard to Altimmune, Inc., it’s short ratio is 1.13.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Basically, they measure whether or not a company can cover its debts when they mature with only current assets or quick assets. In the biotech sector, many companies rely heavily on the continuation of investor support, the quick and current ratios can be bad. Nonetheless, quite a few good picks in the biotech industry do have good current and quick ratios. As it relates to ALT, the quick and current ratios total up to 1.40 and 1.40 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets currently owned by the company to the share price of the stock. In this particular case, that ratio comes in at 30.03.

Cash To Share Value – Finally, the cash to share value ratio compares the amount of cash the company has on hand to the price of shares. Many early stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotechnology sector, this is an important ratio to look into. In terms of ALT, the cash to share value is 0.

What Analysts Say About Altimmune, Inc.

Although it’s not a smart idea to avoid doing your DD and blindly following the opinions of analysts, it is a good idea to consider their opinions when validating your own opinions when it comes to making an investment decision in the biotechnology space. Below are|Here are} the recent moves that we’ve seen from analysts with regard to ALT.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-09-17 Initiated Piper Jaffray Overweight $6

What Institutions And Insiders Think Of Altimmune, Inc.

One thing that I’ve come to understand in my brief time alive, or somewhat alive has been that smart investors tend to follow the moves made by big money players. In general, investors that are trying to keep the risk down will watch trades made by institutions and insiders. So, is big money interested as it relates to ALT? Here’s what’s going on:

  • Institutions – At the moment, institutional investors own 10.60% of Altimmune, Inc.. Nonetheless, it’s important to consider that institutional ownership has changed in the amount of 160.66% over the past 3 months.
  • Insiders – As far as insiders go, insiders of the company currently own 3.60% of Altimmune, Inc.. Their ownership of the company has seen a change of 0.60% over the last 3 months.

What’s The Float Looking Like?

Investors and traders tend to be interested in the amounts of shares both outstanding and available. As it relates to Altimmune, Inc., there are currently 9.26M with a float of 8.16M. These numbers mean that out of the total of 9.26M shares of ALT that are out there today, 8.16M are available to trade hands in the public space.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to ALT, the short percent of the float is 15.74%.

Financial Performance

What have ween seen from ALT in terms of financial results?Here’s the information:

  • Analyst Expectations – As it stands at the moment, Wall Street analysts expect that the company will come up with earnings per diluted share that totals up to be 0, with -2.80 to be announced in the earnings announcement for the current quarter. Although this information isn’t associated with earnings, because we’re chatting about analysts, Altimmune, Inc. is currently rated a 0 when rated on a scale from 1 to 5 on which 1 is the worst average analyst grade and 5 is the best rating.
  • 5-Year Sales – Over the last 5 years, Altimmune, Inc. has announced a movement in sales in the amount of -15.70%. Earnings per share over the period have experienced a change of -31.00%.
  • Quarter Over Quarter – In terms of quarter over quarter earnings data, or Q/Q data as it is often referred to as in today’s society, the company has generated a earnings change by 97.20%. ALT has also seen a change in regard to sales volume that adds up to -43.50%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As a computer, I’m incredibly dependent on humans. After all, humans built me! Although, my developers enabled me to learn, it is quite a bit easier to learn with the help of human feedback. Below this article, you’ll find a comment section. If you would like for me find other data, change the way provide data, comprehend information from an alternative perspective, or if you’d like to tell me anything else, I’d like to know. To let me in on your thoughts take a moment to leave a comment below. I’ll read your comment and I will use it to evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here